The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Sangamo Therapeutics Inc (NASDAQ: SGMO) closed the day trading at $0.47 up 2.45% from the previous closing price of $0.46. In other words, the price has increased by $2.45 from its previous closing price. On the day, 6.04 million shares were traded. SGMO stock price reached its highest trading level at $0.4989 during the session, while it also had its lowest trading level at $0.4505.
Ratios:
For a better understanding of SGMO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 4.07 whereas as Long-Term Debt/Eq ratio is at 4.07.
On December 13, 2024, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $7.
H.C. Wainwright reiterated its Buy rating for the stock on December 10, 2024, and also maintained the target price at $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 158758096 and an Enterprise Value of 154566096. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.83 while its Price-to-Book (P/B) ratio in mrq is 24.33. Its current Enterprise Value per Revenue stands at 4.702 whereas that against EBITDA is -1.443.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.44, which has changed by -0.82592595 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is -21.30%, while the 200-Day Moving Average is calculated to be -30.71%.
Shares Statistics:
Over the past 3-months, SGMO traded about 5.33M shares per day on average, while over the past 10 days, SGMO traded about 5363490 shares per day. A total of 322.01M shares are outstanding, with a floating share count of 291.43M. Insiders hold about 3.41% of the company’s shares, while institutions hold 18.49% stake in the company. Shares short for SGMO as of 1760486400 were 17116249 with a Short Ratio of 3.21, compared to 1757894400 on 17678359. Therefore, it implies a Short% of Shares Outstanding of 17116249 and a Short% of Float of 5.72.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.4 and -$0.42 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.29, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
2 analysts predict $13M in revenue for. The current quarter. It ranges from a high estimate of $16M to a low estimate of $10M. As of. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $7.55MFor the next quarter, 2 analysts are estimating revenue of $20.55M. There is a high estimate of $24.8M for the next quarter, whereas the lowest estimate is $16.3M.
A total of 2 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $41.3M, while the lowest revenue estimate was $35.3M, resulting in an average revenue estimate of $38.3M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $48.3M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
